Gelatin Patents (Class 424/456)
-
Publication number: 20110212170Abstract: A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.Type: ApplicationFiled: April 14, 2011Publication date: September 1, 2011Inventors: Günter Ditzinger, Bernhard Gabriel, Anne-Hortense Schmitt-Hoffmann, Lutz Wevelsiep
-
Publication number: 20110206763Abstract: A rapid-release encapsulation composition that includes a gelatin and a water-insoluble rapid-release agent is provided. In particular, a rapid-release encapsulation composition that includes a gelatin and an insoluble carbonate salt is provided.Type: ApplicationFiled: February 18, 2011Publication date: August 25, 2011Applicant: GelitaInventors: Tom Keenan, John M. Dolphin
-
Publication number: 20110200669Abstract: Compositions and a methods are described for treating disorders of the small and large bowel, such as Crohn's disease, ulcerative colitis and irritable bowel syndrome, without producing any treatment-related systemic side effects and with minimal or no abdominal discomfort. A method of administration of civamide that is incorporated into soft gelatin capsules and administered with meals is described. Surprisingly, the method provides for diminishment of pain and inflammation of the small and large bowel without producing any systemic side effects or significant abdominal discomfort.Type: ApplicationFiled: February 15, 2010Publication date: August 18, 2011Applicant: WINSTON LABORATORIES, INC.Inventor: Joel E. Bernstein
-
Publication number: 20110189091Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.Type: ApplicationFiled: April 20, 2010Publication date: August 4, 2011Inventor: Dale R. Bachwich
-
Patent number: 7989005Abstract: A soft gelatin capsule and method to deliver an efficable dose of Lagerstroemia speciosa L. (marketed by Soft Gel Technologies under the trademark Glucosol™) for the assistance and maintenance of moderate weight loss through blood sugar maintenance. The product relies on the effects of corosolic acid on blood sugar levels to derive a healthy weight loss effect for Type II diabetics (non-insulin dependent) and healthy non-diabetics and the improved absorption of an oil based delivery system. The product provides safe and sustainable weight loss when combined with a restricted calorie diet and regular exercise. Its benefits include improvement of cardiovascular health, normalized blood sugar levels, and improved physical appearance with the positive psychological effects associated with successful and safe weight loss/maintenance.Type: GrantFiled: September 6, 2006Date of Patent: August 2, 2011Assignee: Soft Gel Technologies, Inc.Inventors: Ronald G. Udell, Siva P. Hari
-
Patent number: 7988995Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.Type: GrantFiled: July 30, 2002Date of Patent: August 2, 2011Assignee: Watson Laboratories, Inc.Inventors: Vinayak T. Bhalani, Satishchandra P. Patel
-
Patent number: 7985770Abstract: Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (i): comprising the step of: admixing the same with a polyol and/or a fatty acid ester other than glyceride and a composition obtained by the method. In addition a soft gelatin capsule formulation of the compound of formula (I) obtained by incorporating the compound in a soft gelatin capsule shell comprising gelatin and a polyol plasticizer.Type: GrantFiled: January 23, 2007Date of Patent: July 26, 2011Assignees: Sucampo AG, R-Tech Ueno, Ltd.Inventors: Ryu Hirata, Yasuhiro Harada, Ryuji Ueno
-
Patent number: 7981911Abstract: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.Type: GrantFiled: July 31, 2008Date of Patent: July 19, 2011Assignee: Abbott LaboratoriesInventors: Laman Alani, Soumojeet Ghosh
-
Publication number: 20110171299Abstract: The present invention is a solid dosage form of a doxycycline metal complex. The present invention also includes a process for making a doxycycline metal complex in a solid dosage form. The process comprises the steps of (i) providing an aqueous solution of doxycycline or a physiologically acceptable salt thereof; (ii) admixing a metal salt with the aqueous solution; (iii) admixing a base to increase the pH of the aqueous solution, thereby forming a suspension of doxycycline metal; and (iv) drying the suspension, thereby forming a dry granulation of doxycycline metal complex.Type: ApplicationFiled: December 18, 2008Publication date: July 14, 2011Applicant: Warner Chilcott Company, Inc.Inventors: Tina deVries, Lynn Gold
-
Publication number: 20110171300Abstract: A compound of formula (I) wherein R is selected from (i) a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, which is optionally substituted by one or more groups independently selected from halo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; (ii) (C1-C6)alkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; (iii) (C1-C6)alkyl substituted by (C3-C13)cycloalkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; and (iv) (C3-C13)cycloalkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl.Type: ApplicationFiled: February 14, 2008Publication date: July 14, 2011Applicant: RESOLUTION CHEMICALS LIMITEDInventors: Parveen Bhatarah, Kevin John Batchelor, Derek Mchattie, Alan Kenneth Greenwood
-
Publication number: 20110171297Abstract: The invention provides a sustained release composition that; (1). Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or totally coated by a functional coating layer or film. (2). Delivers the drug substance within 24 hours and is therefore suitable for once daily administration of the said drug substance. (3). Exhibits linearity between the strength dosage form and the (total mass of the dosage form, by proportional increase of the amounts of the drug substance and the excipients in the formulation. (4). Is possible to be divided in smaller doses, without affecting the release of the drug substance. The invention provides a sustained release capsule formulation containing an appropriate number of functional complex mini tablets comprising of: (1).Type: ApplicationFiled: March 23, 2011Publication date: July 14, 2011Applicant: PHARMATHEN S.A.Inventors: EVANGELOS KARAVAS, KONSTANTINOS LIOUMIS, STAVROS POLITIS
-
Publication number: 20110171301Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.Type: ApplicationFiled: January 14, 2011Publication date: July 14, 2011Inventor: Michael Mutz
-
Patent number: 7972621Abstract: The invention disclosed herein relates to a pharmaceutical composition comprising a carrier and an active ingredient, wherein the carrier is at least one fish gelatin predetermined on the basis of the molecular weight profile of the gelatin. In some embodiments, particularly when the concentration of carrier comprises a relatively lower percentage of the total composition, the carrier may be exclusively a high molecular weight fish gelatin, or may be comprised of a mixture with standard molecular weight gelatin in which high molecular weight gelatin comprises a predominant portion. In those embodiments where the concentration of carrier comprises a relatively larger percentage of the total composition, the carrier may be an exclusively standard molecular weight fish gelatin, or may be comprised of a mixture in which standard molecular weight gelatin comprises a predominant portion. Thus, compositions may be designed to optimize performance for various required gelatin concentration formulations.Type: GrantFiled: June 3, 2004Date of Patent: July 5, 2011Assignee: R.P. Scherer Technologies, LLCInventors: Desmond Yik Teng Wong, Leon Paul Grother, Andrzej Jan Brzozowski
-
Publication number: 20110159088Abstract: The field of the present invention is that of oral pharmaceutical forms of at least one active principle AP whose solubility varies greatly as a function of the gastric pH, and also treatments and administration methods relating thereto. The invention relates to the use, in an oral pharmaceutical form comprising AP, of a coating or of a matrix including the said AP and allowing the controlled release of the said AP, in order for this form administered orally to a sample of individuals to lead, irrespective of the fed or fasted state of the individuals, to a reduction in the inter- and/or intra-individual standard deviation of the Cmax, which makes it possible to ensure lower variability of the efficacy and of the therapeutic safety of the pharmaceutical form, compared with an immediate-release AP pharmaceutical form administered to this same sample of individuals, at the same dose.Type: ApplicationFiled: May 24, 2006Publication date: June 30, 2011Applicant: Flamel Technologies, S.A.Inventors: Florence Guimberteau, Gérard Soula
-
Publication number: 20110135721Abstract: Composition comprising an anti-inflammatory plant extract from rosehips together with a cartilage-protective substance, and a method of producing the rosehip extract.Type: ApplicationFiled: December 19, 2008Publication date: June 9, 2011Applicant: Finzelberg GmbH & Co., KGInventors: Bernd Walbroel, Björn Feistel, Ivo Pischel
-
Publication number: 20110129518Abstract: An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encapsulation protects the viability of the probiotic microbes against unfavorable temperatures. An exemplary embodiment providing one or more improvements includes methods of using viable probiotics in therapy of birds and mammals infected with infectious diseases. Probiotics acted as adjuvants in stimulating antibody reaction and stimulated a cellular immunity response. In particular, probiotics were shown to reduce the number of viable oocytes from fecal samples, stimulate antibody production, and stimulate of proliferation of splenocytes in chickens infected with Eimeria. In addition, probiotics were shown to relieve symptoms of parvovirus infection in dogs.Type: ApplicationFiled: November 2, 2010Publication date: June 2, 2011Applicant: IMAGILIN TECHNOLOGY LLCInventor: Jhy-Jhu Lin
-
Publication number: 20110129529Abstract: An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encapsulation protects the viability of the probiotic microbes against unfavorable temperatures. An exemplary embodiment providing one or more improvements includes methods of using viable probiotics in therapy of birds and mammals infected with infectious diseases. Probiotics acted as adjuvants in stimulating antibody reaction and stimulated a cellular immunity response. In particular, probiotics were shown to reduce the number of viable oocytes from fecal samples, stimulate antibody production, and stimulate of proliferation of splenocytes in chickens infected with Elimeria. In addition, probiotics were shown to relieve symptoms of parvovirus infection in dogs.Type: ApplicationFiled: November 2, 2010Publication date: June 2, 2011Applicant: IMAGILIN TECHNOLOGY LLCInventor: Jhy-Jhu Lin
-
Publication number: 20110123611Abstract: Peptide and peptides that may be covalently linked to a lipid and methods of using such peptides and lipopeptides to prevent or treat disease are disclosed herein.Type: ApplicationFiled: April 24, 2009Publication date: May 26, 2011Applicant: THERIMUNEX PHARMACEUTICALS, INC.Inventor: James D. Thacker
-
Publication number: 20110123610Abstract: The present invention is directed to an extended release pharmaceutical composition such as tablets and capsules, and in particular to a matrix tablet composition comprising a therapeutically effective quantity of Tolterodine or pharmaceutical acceptable salts thereof incorporated in a hydrophobic matrix comprising water insoluble polymer and wax and a method for the preparation thereof.Type: ApplicationFiled: November 22, 2010Publication date: May 26, 2011Applicant: MICRO LABS LIMITEDInventors: Rajesh KSHIRSAGAR, Sachin MUNDADE, Ganesh SHINDE, Pravin KAMBLE, Sandip SONAWANE, SM MUDDA
-
Publication number: 20110117191Abstract: The invention relates to a substance mixture on the basis of a mixture of essential oils, wherein the oil mixture contains juniper oil and turpentine oil, in particular turpentine oil of the duster pine type or substantially comprises them, and wherein the substance mixture preferably furthermore contains a liquid and/or dissolved active ingredient or a mixture of a plurality thereof and/or an active ingredient in powder form or a mixture of a plurality thereof.Type: ApplicationFiled: October 13, 2010Publication date: May 19, 2011Inventor: Marianne Brøndlund
-
Publication number: 20110111020Abstract: Single-core and multi-core microcapsules are provided, having multiple shells, at least one of which is formed of a complex coacervate of two components of shell materials. The complex coacervate may be the same or different for each shell. Also provided are methods for making the microcapsules.Type: ApplicationFiled: January 19, 2011Publication date: May 12, 2011Applicant: OCEAN NUTRITION CANADA LIMITEDInventors: Nianxi YAN, Yulai JIN
-
Patent number: 7939106Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: May 23, 2003Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Patent number: 7939105Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: November 19, 1999Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Patent number: 7935365Abstract: This invention provides a preparation comprising serine glycerophospholipids which comprise a mixture of serine glycerophospholipids comprising eicosapentaenoic acid (EPA) and serine glycerophospholipids comprising docosahexaenoic acid (DHA), wherein each such serine glycerophospholipid comprising EPA and each such serine glycerophospholipid comprising DHA has the formula (I): wherein R? is serine; wherein one of R or R? is acyl EPA or acyl DHA and the other of R or R? is hydrogen or an acyl group; wherein the combined amount of EPA and DHA present in such mixture of serine glycerophospholipids constitutes 10-50% by weight of the total fatty acids content of the serine glycerophospholipids in said preparation; and wherein the mixture is not identical to naturally occurring human or mammalian brain PS.Type: GrantFiled: June 24, 2008Date of Patent: May 3, 2011Assignee: Enzymotec, Ltd.Inventors: Gai Ben Dror, Dorit Platt, Orly Farkash, Rassan Zuabi, Zohar Bar-On, Avidor Shulman, Dori Pelled, Yael Richter
-
Publication number: 20110097398Abstract: The invention relates to compositions and methods for reducing cross-linking in the gelatin shell of gelatin capsules by incorporation of free amino acid into the capsule shell and by inclusion of an ester of carboxylic acid either into the capsule filling, and/or into the capsule shell and/or into the lubrication agent, or in combinations thereof. Described are soft gelatin capsules characterized by improved stability as compared with gelatin capsules that do not contain amino acid in the shell and carboxylic acid ester in the filling, shell or in the lubrication agent, or in combinations thereof.Type: ApplicationFiled: June 5, 2003Publication date: April 28, 2011Inventors: Ales Vrána, Tomás Andrýsek, Alexandr Jegorov, Richard Szrajber
-
Publication number: 20110091539Abstract: The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.Type: ApplicationFiled: December 22, 2010Publication date: April 21, 2011Applicant: Wyeth LLCInventors: Arwinder S. Nagi, Ramarao Chatlapalli, Shamim Hasan, Rolland W. Carson, Mohamed Ghorab
-
Publication number: 20110086094Abstract: The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the prevention of cardiovascular diseases in high-risk populations.Type: ApplicationFiled: March 25, 2009Publication date: April 14, 2011Applicants: Ferrer Internacional S.A., Fundacion Centro Nacional de Investigaciones Cardi ovasculares Carlos IIIInventors: Marta Guerrero, Anna Orriols, Pablo Martín, Manuel Raga
-
Patent number: 7910114Abstract: The present invention provides methods of treating a human or other mammal infected with a parasitic microorganism by administering an effective amount in unit dosage form of a C8-C16-alpha, beta-unsaturated aliphatic aldehyde, such as trans-2-dodecenal, to the human or other mammal. The parasitic microorganisms may include trypanosomes, bacteria, fungi and nematodes.Type: GrantFiled: August 15, 2007Date of Patent: March 22, 2011Assignee: Slippery Rock University FoundationInventors: Wayne M. Forbes, Carolyn Steglich
-
Publication number: 20110064803Abstract: The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis.Type: ApplicationFiled: May 9, 2006Publication date: March 17, 2011Applicant: ELAN PHARMA INTERNATIONAL LIMITED.Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
-
Publication number: 20110059168Abstract: The method includes steps of providing non-pathogenic glutamine-synthetase-producing bacteria, introducing the provided non-pathogenic glutamine-synthetase-producing bacteria into intestines, releasing the introduced non-pathogenic glutamine-synthetase-producing bacteria in the intestines in a predetermined time period, and normalizing serum level of free glutamate and halting continual flooding of free glutamate into the brain.Type: ApplicationFiled: September 9, 2009Publication date: March 10, 2011Inventors: Sam ANG, Daniel Kuang Hsien Wu
-
Publication number: 20110052682Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.Type: ApplicationFiled: December 15, 2009Publication date: March 3, 2011Inventors: Aqeel Fatmi, Tae Kyoung Kim, Karla E. Madrigal
-
Patent number: 7897728Abstract: The present invention provides a process to make a gelatine hydrolysate, a gelatine hydrolysate, and gelatine compositions including gelatine hydrolysates. More specifically, the invention provides gelatine compositions having a reduced tendency to cross-link and improved dissolution properties.Type: GrantFiled: May 31, 2006Date of Patent: March 1, 2011Assignee: Gelita AGInventors: John M. Dolphin, Jason D. Russell
-
Publication number: 20110045066Abstract: The present invention refers to a new compound containing Silymarin with Carbopol for the treatment of Diabetes Mellitus. This compound morphologically and structurally regenerates the damage that occurs in the pancreatic tissue in Diabetes Mellitus, and regenerates the insulin-producing pancreatic cells (? cells). It therefore regulates the serum levels of this hormone. Furthermore, it restores and maintains the normal concentrations of the blood glucose.Type: ApplicationFiled: May 1, 2009Publication date: February 24, 2011Applicant: Universidad Autonoma MetropolitanaInventor: Claudia Angelica Soto Peredo
-
Publication number: 20110045067Abstract: The invention relates to soft gelatin capsules containing at least one pharmaceutical, wherein the capsule shell includes carrageenan and cold water fish gelatin or a mixture of cold fish gelatin and warm fish gelatin.Type: ApplicationFiled: January 29, 2009Publication date: February 24, 2011Applicant: AYANDA ASInventors: Ingvild Johanne Haug, Kurt Ingar Draget
-
Publication number: 20110033530Abstract: A coating composition for the enteric coating of capsule halves made of water-soluble or water-swellable polymer material in a dipping process is provided. The composition is an aqueous dispersion or solution, containing a polymer mixture of at least one first (meth)acrylate copolymer, which is enteric, and at least one further (meth)acrylate copolymer, which is enteric or water-insoluble, and also auxiliaries which influence the viscosity of the dispersion and the elasticity of the dried polymer film. The solids content of the dispersion or solution is more than 25% by weight and the viscosity is 150 to 1500 mPa·s and a dried film produced from the dispersion or solution has an elongation at break of at least 200%. Also provided is a capsule composed of two capsule halves coated with the dispersion or solution in a dipping process does. The enteric capsule does not dissolve in 0.1 N HCl at pH 1.2 after two hours, but completely dissolves in buffer at pH 6.8 in less than 30 minutes.Type: ApplicationFiled: July 29, 2010Publication date: February 10, 2011Applicant: Evonik Roehm GmbHInventors: Brigitte SKALSKY, Manfred Assmus, Odette Hensel, Hans-Ulrich Petereit
-
Publication number: 20110033528Abstract: The invention provides an oral dosage form for the anti-cancer drug picoplatin comprising a core and a coating, the dosage form being free of redox-active metal salts. The core of the tablet is a substantially dry powder comprising about 10 to 60 wt % picoplatin wherein the picoplatin is a particulate of less than about 10 microns average particle diameter, about 40-80 wt % of a filler comprising a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate, and an effective amount of up to about 5 wt % of a lubricant. The dosage form can further include a dispersant.Type: ApplicationFiled: August 5, 2009Publication date: February 10, 2011Applicant: Poniard Pharmaceuticals, Inc.Inventors: Alistair J. Leigh, Christopher A. Procyshyn, Ernest S.Y. Wong, Christen M. Giandomenico
-
Publication number: 20110033531Abstract: An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of ?-tocotrienol, ?-tocotrienol, ?-tocotrienol, or ?-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg ?-tocotrienol.Type: ApplicationFiled: August 9, 2010Publication date: February 10, 2011Applicant: DRACOPHARMA, INC.Inventor: Steven C. Quay
-
Publication number: 20110033529Abstract: Pharmaceutically acceptable liquid paricalcitol formulations intended for oral administration, processes for preparing such formulations, and methods of using the same. Embodiments relate to liquid paricalcitol formulations filled into gelatin capsules.Type: ApplicationFiled: October 14, 2009Publication date: February 10, 2011Inventors: Durga Prasad Samantaray, V. Nageswara Rao, Ravi Kumar Namballa, Bhushan Subhash Yeola
-
Publication number: 20110027356Abstract: Oral pharmaceutical dosage form containing at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another, at least one of the medicaments being selected from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, clopidogrel.Type: ApplicationFiled: January 26, 2009Publication date: February 3, 2011Inventors: Anne-Emmanuelle Lugrin, Claude Griscelli, Mehdi El Glaoui, Guillaume El Glaoui, Jean Hoffelt
-
Publication number: 20110027357Abstract: A timed or controlled release composition is provided where a plurality of active pellets is layered with a controlled release layer whereby the single functional component of the controlled release layer is shellac and/or a shellac based material.Type: ApplicationFiled: October 8, 2010Publication date: February 3, 2011Inventor: Isaac Gilinski
-
Publication number: 20110020440Abstract: The present invention relates to a stable pharmaceutical composition comprising soft gelatin capsules containing at least one sparingly soluble active drug (singly or in combination with sparingly soluble and/or soluble drugs) and a solvent system, wherein the solvent system comprises of solvent, co-solvent, solubilizer(s), surfactant, aqueous solution of alkali and crystal growth inhibitor. The present invention further relates to process for preparing a stable pharmaceutical composition of sparingly soluble active drug(s) in soft gelatin capsules.Type: ApplicationFiled: November 15, 2008Publication date: January 27, 2011Applicant: CADILA PHARMACEUTICALS LIMITEDInventors: Indravadan Ambalal Modi, Bakulesh Mafatlal Khamar, Ashok Sitaram Omray, Vandana Patravale, Kartik Yogesh Shah, Prashant Yogesh Patel
-
Publication number: 20110014248Abstract: The present invention relates to a use of an effective amount of at least one probiotic microorganism and/or a fraction thereof and/or a metabolite thereof for preventing and/or treating dandruff disorders of the scalp, as well as a cosmetic process for preventing and/or treating a dandruff condition including the administration a first cosmetic active agent and of at least a second cosmetic active agent, topically, the said first and second cosmetic active agents being formulated in separate compositions, the first cosmetic active agent being chosen from probiotic microorganisms, and mixtures thereof, and the second cosmetic active agent being chosen from antidandruff active agents.Type: ApplicationFiled: March 15, 2010Publication date: January 20, 2011Applicants: L'OREAL, NESTEC SAInventors: Isabelle Castiel, Audrey Gueniche
-
Publication number: 20110014278Abstract: The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterised in that it further comprises particles at least 50% of which have a mean diameter greater than 250 ?m. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products.Type: ApplicationFiled: February 6, 2006Publication date: January 20, 2011Applicant: VIRBAC SAInventor: Guy Derrieu
-
Publication number: 20110014131Abstract: Small scale and nanoscopic identification features can be fabricated for pharmaceutical capsules. A composition comprising a capsule component, wherein the capsule component comprises a gelled pharmaceutical capsule material and at least one surface, wherein the at least one surface comprises at least one integral feature with a lateral dimension smaller than about 100 microns, or less than one micron. Methods of making the same are described by gelation with heating or cooling. The compositions and methods can be used for anti-counterfeiting.Type: ApplicationFiled: July 19, 2010Publication date: January 20, 2011Inventors: Sandeep Disawal, Bjoem Rosner, Robert J. Janosky
-
Publication number: 20100330171Abstract: Nutritional supplements for eye health comprising: an anti-oxidant component; an anti-inflammatory component; and an anti-angiogenic component. The supplements inhibit development and progression of a range of retinal diseases and degenerations, particularly AMD and diabetic eye disease, diabetic retinopathy and diabetic macular edema. The supplements include tocotrienol and green tea extract.Type: ApplicationFiled: January 21, 2010Publication date: December 30, 2010Inventors: Jeffrey P. Gilbard, Johanna M. Seddon
-
Patent number: 7858118Abstract: An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (Tmax) of greater than 10 hours, and peak Tramadol plasma concentration (Cmax) which are less than three times the plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.Type: GrantFiled: April 11, 2002Date of Patent: December 28, 2010Assignee: Galephar Pharmaceutical Research, Inc.Inventors: Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
-
Publication number: 20100316695Abstract: The invention relates to a condensation product obtainable by reaction of a1) at least one bicyclic or polycyclic aromatic or heteroaromatic, where the bicyclic or polycyclic aromatic or heteroaromatic is substituted by at least one carboxyl group (—COOH), and where the carboxyl group can be present in salt form, a2) at least one carbonyl compound, a3) if appropriate at least one sulfonating agent, a4) at least one urea derivative, and a5) if appropriate at least one further aromatic or heteroaromatic, or a physiologically tolerable salt thereof.Type: ApplicationFiled: November 11, 2008Publication date: December 16, 2010Applicant: BASF SEInventors: Sebastien Garnier, Stephan Hueffer, Guenter Scherr, Joachim Roser, Ulrich Mrowietz, Hans Wilhelm Doerr, Jindrich Cinatl, Martin Michaelis
-
Patent number: 7850991Abstract: A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.Type: GrantFiled: December 23, 2004Date of Patent: December 14, 2010Assignee: Wisconsin Alumni Research FoundationInventor: Hector F. DeLuca
-
Publication number: 20100310650Abstract: A pharmaceutical composition for the oral administration of omega polyenoic fatty acids combined with one or more active principles incompatible therewith, is described; also described is a process for preparing said pharmaceutical composition.Type: ApplicationFiled: June 26, 2007Publication date: December 9, 2010Inventor: Roberto Valducci
-
Publication number: 20100303903Abstract: The invention relates to methods of enhancing selective serotonin reuptake inhibitor effects in mammals. In particular, the invention provides methods for treating selective serotonin reuptake inhibitor dependent conditions such as depression. More specifically, the present invention relates to a method of increasing the antidepressant activity of a selective serotonin reuptake inhibitor (“SSRI”) by administering L-lysine-d-amphetamine in combination with an SSRI and to formulates containing the same. In a preferred aspect, the combination is administered in connection with a method of treating depression. One preferred SSRI is escitalopram. The preferred amphetamine prodrug is L-lysine-d-amphetamine.Type: ApplicationFiled: May 26, 2010Publication date: December 2, 2010Applicant: SHIRE LLCInventor: David HACKETT